Other Events. On August 25, 2026, Boston Scientific Corporation (the “ Company ”) identified a cybersecurity incident affecting certain of its information technology systems that has resulted in a global disruption to the Company’s operations. Upon detection, the Company activated its incident response protocols and began an investigation with the assistance of third-party cybersecurity experts to assess and to contain the threat. The incident has caused, and is expected to continue to cause,…

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Costs Associated with Exit or Disposal Activities. On July 21, 2026, the Board of Directors of Boston Scientific Corporation (the “Company”) approved a new global restructuring program (the “2026 Restructuring Plan”). The 2026 Restructuring Plan is intended to support the Company’s efforts to drive sustained cost efficiencies and enable continued growth by ensuring that the Company is structured and resourced to support its strategic priorities. Key activities under the 2026 Restructuring Pla…

Other Events. Investment Agreement with MiRus LLC On May 18, 2026, Boston Scientific Corporation (the “ Company ”) issued a press release announcing that the Company has entered into an investment agreement (the “ Investment Agreement ”) with MiRus LLC (“ MiRus ”), a privately held company developing and commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the Siegel transcatheter aortic valve…

Other Events. Accelerated Share Repurchase Program On May 18, 2026, Boston Scientific Corporation (the “ Company ”) issued a press release announcing that the Company has entered into an accelerated share repurchase (“ ASR ”) agreement with JPMorgan Chase Bank, National Association for $2 billion (the “ Repurchase Price ”) of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, the Company will pay the repurchase price an…

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. With respect to the 2026 Credit Agreements, the information set forth above under

Entry into a Material Definitive Agreement. Revolving Credit Agreement On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. The Company may borrow from time to time up to $3,000,000,000 in revolving credit loans under the 2026 Revolving C…

Termination of a Material Definitive Agreement. In connection with the entry into the 2026 Revolving Credit Agreement, on February 26, 2026, the Company terminated a prior revolving credit agreement, dated as of May 10, 2021, as amended by that certain Amendment to the Credit Agreement dated as of December 21, 2022, the Second Amendment to the Credit Agreement, dated as of March 1, 2023, and the Third Amendment to the Credit Agreement, dated as of May 10, 2024, by and among the Company, as bo…

Other Events. On February 18, 2026, the Board approved an increase to the Company’s existing authorization to repurchase up to $1.0 billion of the Company’s common stock, par value $0.01 per share (“ Common Stock ”), by an additional $4.0 billion. As a result, the Company is authorized to repurchase up to a total of $5.0 billion of Common Stock under the Company’s stock repurchase program, all of which remains available as of the date hereof.

Director — Catherine R. Smith, Christophe P. Weber: The Board of Directors increased the number of directors and appointed two new external directors.

Director — Yoshiaki Fujimori: Mr. Yoshiaki Fujimori will not stand for re-election at the Company’s 2026 Annual Meeting.

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On January 14, 2026, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Pinehurst Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Penumbra, Inc., a Delaware corporation (“ Penumbra ”), providing for the merger of Merger Sub with and into Penumbra (the “ Merger ”), with Penumbra surviving the Merg…

of this Current Report on Form 8-K, as well as Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Cautionary Statement Regarding Forward-…

The filing describes a new annual bonus plan for employees, including executives.

Director — John E. Sununu: Mr. Sununu will not stand for re-election at the Company’s 2026 Annual Meeting.

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Executive Vice President and President, Peripheral Interventions — Jeffrey B. Mirviss: Mr. Jeffrey B. Mirviss is retiring from his role and will serve as a senior advisor until February 27, 2026.

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Other Events. On May 28, 2025, Boston Scientific Corporation (the “Company”) announced it is discontinuing worldwide sales of the ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems and no longer pursuing U.S. FDA approval for ACURATE or approval in other geographies. The Company made this decision based on recent discussions with regulators, which resulted in increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new reg…

Chief Financial Officer — Daniel J. Brennan and Jonathan Monson: Daniel J. Brennan is retiring as CFO, and Jonathan Monson has been promoted to replace him.

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Creation of a Direct Financial Obligation of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. On February 21, 2025, Boston Scientific Corporation (the “Company”), as guarantor, and American Medical Systems Europe B.V. (“AMS Europe”), its wholly owned finance subsidiary, as issuer, entered into an Underwriting Agreement (as supplemented by the Terms Agreement, also dated February 21, 2025, the “Underwriting Agreement”), among the Company, AMS Europe and the several underwriters named in the Underwriting Agreement (the “Underwriters”), in conn…